PhRMA Targets High Cost-Sharing For Drugs In Comments To CMS
Executive Summary
The Pharmaceutical Research and Manufacturers of America is highlighting the negative impact high cost-sharing can have on patient access to drugs, most recently in comments on the draft 2010 "call letter" for Part D plans